Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga
Author:
- 1 May 2002
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 12 (5) , 709-724
Abstract
Validation of integrase as a suitable therapeutic target for the development of drugs against HIV infection; discovery of diketo acid derivatives as bona fide inhibitors of integrase and the recent news of Phase II clinical trials with S-1360 are major findings fuelling the recent surge of interest in the development of integrase inhibitors. Herein, the first review of the entire patent literature for small molecule intergrase inhibitors is presented. The emphasis is based on compounds with potential to serve as leads, therefore, no attempts are made to include: antibodies, oligonucleotides or polypeptides.Keywords
This publication has 28 references indexed in Scilit:
- New Paradigms in Drug Design and DiscoveryCurrent Topics in Medicinal Chemistry, 2002
- Structure-based HIV-1 integrase inhibitor design: a future perspectiveExpert Opinion on Investigational Drugs, 2001
- HIV-I integrase inhibitors: Past, present, and future2000
- HIV-1 Integrase as a Target for Antiviral DrugsAntiviral Chemistry and Chemotherapy, 1997
- Design and discovery of HIV-1 integrase inhibitorsDrug Discovery Today, 1997
- In VitroAssays for Activities of Retroviral IntegraseMethods, 1997
- HIV cDNA integrationAIDS, 1996
- A novel assay for the DNA strand-transfer reaction of HIV-1 integraseNucleic Acids Research, 1994
- Inhibitors of human immunodeficiency virus integrase.Proceedings of the National Academy of Sciences, 1993
- HIV-1 Integrase: High-Level Production and Screening Assay for the Endonucleolytic ActivityAntiviral Chemistry and Chemotherapy, 1992